Australia ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

Australia ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis


$ 3999

Australia's ADHD therapeutics market is expected to witness growth from $355 Mn in 2022 to $707 Mn in 2030 with a CAGR of 9% for the year 2022-30. The increasing prevalence of ADHD in Australia and the rise in demand for innovative treatment options for its treatment and more investments by pharmaceutical companies in ADHD drugs are the potential growth drivers for the market. The Australia ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Zucero Therapeutics, Atherton Pharmaceuticals, and Novartis are the major players operating in the market.

ID: IN10AUPH028 CATEGORY: Pharmaceuticals GEOGRAPHY: Australia AUTHOR: Parul Choudhary

Buy Now

Australia Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

Australia Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $355 Mn in 2022 and is projected to reach $707 Mn in 2030, exhibiting a CAGR of 9% during the forecast period. A total of $105.8 Bn, or 16.8% of total government expenditures in Australia, is projected to be spent on health in 2022–2023. In 2022–2023, the Australian Government's Pharmaceutical Benefits Scheme (PBS) medicine payments will account for the majority of the $17.2 Bn, or 16.3%, in pharmaceutical benefits and services. To support the proposals of the Strengthening Medicare Taskforce, which are due by the end of this year, the government has set aside $750 Mn for its Strengthening Medicare Fund.

Attention deficit hyperactivity disorder is a developmental disorder that starts in childhood. Children with ADHD may struggle to focus and become hyperactive, to the point where the condition interferes with their schoolwork, friendships, or family life. One in twenty Australians suffers from ADHD. Boys are more likely to have it. More than 3 out of 4 kids who are diagnosed with ADHD still exhibit the symptoms as adults. Executive functioning, or the capacity to self-regulate and control ideas, words, actions, and emotions, is impacted by ADHD.

Depending on the particular requirements of each child and family, there are multiple options for treating ADHD. Utilizing effective parenting techniques is frequently the first move. Maintaining a routine, assisting the kid in developing social skills, and working with the school to create a learning environment can all be beneficial. A combination of treatments including medication, psychotherapy, education, and knowledge treatments for adults can include medication, psychotherapy, education, or training in Australia. Both short-acting and long-acting medicines are available in Australia in a variety of forms. The most popular and well-known ADHD treatments are stimulants. When taking these quick-acting drugs, between 70 and 80 % of kids with ADHD experience reduced ADHD symptoms. In 2003, non-stimulants were authorized for the therapy of ADHD. Although they don't work as rapidly as stimulants, they can still have an impact for up to 24 hours. The most frequently recommended medications for ADHD are the stimulants methylphenidate and dexamphetamine in Australia. For some individuals, second-line treatments like tricyclic antidepressants, clonidine, moclobemide, and thioridazine have been used alone or in conjunction with a stimulant. The effectiveness of the other drugs has not yet been determined, despite the tricyclics having a comparable efficacy to that of the stimulants.

australia attention deficit hyperactivity disorder therapeutics market analysis

Market Dynamics

Market Growth Drivers

Due to an increase in the number of diagnosed cases, there has been a steady rise in the demand for ADHD medications in Australia. In response to this, the Australia ADHD therapeutics market has expanded as pharmaceutical firms have introduced new medications to meet the rising demand. The treatment choices for ADHD have significantly improved, primarily due to the development of long-acting drugs and non-pharmacological therapies. Because patients and healthcare professionals now have more choices for treating the disorder, this has helped the Australia ADHD therapeutics market to expand.

Market Restraints

The reasons most likely to impede the growth of the Australia attention-deficit hyperactivity disorder (ADHD) market in the upcoming years are the strict administration and governing procedures, the rise in drug prices, and the insufficient availability of non-stimulants medicines for ADHD. The quality of life of patients is also being restricted by the contraindications and side effects associated with ADHD medications, which is predicted to further hinder the expansion of the Australia ADHD therapeutics market in the near future.

Competitive Landscape

Key Players

  • Tripak Pharmaceuticals (AUS)
  • AcuraBio (AUS)
  • Kira Biotech (AUS)
  • Zucero Therapeutics (AUS)
  • Atherton Pharmaceuticals (AUS)
  • Novartis
  • Noven Pharmaceuticals
  • Shire
  • Teva Pharmaceutical
  • Impax Laboratories

Healthcare Policies and Regulatory Landscape

A drug must be approved by the Therapeutic Goods Administration (TGA) before it can be sold in Australia. Following the 1991 Baume report, the TGA's duties were rearranged. The TGA must assess the drugs' effectiveness, safety, and quality as well as their timely availability. Referrals to the Australian Drug Evaluation Committee (ADEC) are made for new chemical substances and applications that call for professional counsel. The TGA ultimately decides whether to register a drug for use in Australia, despite the ADEC's ability to make suggestions in this regard. The TGA is in charge of examining non-prescription medications, over-the-counter drugs, alternative medicines, and medical equipment in addition to prescription drugs. Drug regulation is a labor- and resource-intensive procedure. Regarding the quality, security, and effectiveness of medications made accessible in Australia, it must be held accountable. The acceptance of a balance between safety and effectiveness is a part of this responsibility.

Recently the Pharmaceutical Benefits Scheme (PBS) removed the age restriction (previously 18 years) to enable people over the age of 18 to be eligible to have a PBS Script for the treatment of ADHD.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Segmentation

By Drug Type (Revenue, USD Billion):

  • Stimulants
    • Amphetamine
    • Methylphenidate
    • Dextroamphetamine
    • Dexmethylphenidate
    • Lisdexamfetamine
    • Others
       
  • Non-Stimulants
    • Atomoxetine
    • Bupropion
    • Guanfacine
    • Clonidine

By Age Group (Revenue, USD Billion):

  • Pediatric And Adolescent
  • Adult

By Distribution Channel (Revenue, USD Billion):

  • Hospital Pharmacies
  • Speciality Clinics
  • Retail Pharmacies
  • e-Commerce

By Psychotherapy (Revenue, USD Billion):

  • Behavior Therapy
  • Cognitive Behavioral Therapy
  • Interpersonal Psychotherapy
  • Family Therapy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 23 March 2023
Updated by: Shivam Zalke

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up